A Cleveland Clinic study examines the mortality burden of modifiable behavioral risk factors such as obesity, diabetes, tobacco use, high blood pressure and high cholesterol.
Value-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.
• Top 10 emerging industry leaders • Three top criticisms against CMS' hospital star ratings • Autoimmune drug pipeline: What health execs should watch
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%